Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. 1997

C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
Clinica delle Malattie Infettive, Università di Milano, Ospedale Luigi Sacco, Italy.

BACKGROUND Recent research has found that entry of non-syncytium-inducing (NSI), monocyte-macrophage-tropic HIV-1 isolates requires binding to both CD4 and CCR5 receptors, and that delta 32/delta 32 homozygous individuals are protected against infection. OBJECTIVE To analyse the polymorphism of CCR-5 gene in HIV-1-infected and uninfected subjects. METHODS CCR-5 sequences were amplified by polymerase chain reaction (PCR) from DNA of peripheral blood mononuclear cells. Samples from 152 HIV-1-infected subjects and 122 uninfected controls were tested for the detection of the 32 base-pair deletion. HIV-1 phenotype was determined by viral isolation and MT-2 evaluation. RESULTS The wild-type/delta 32 heterozygous and delta 32/delta 32 homozygous conditions were represented in 10.7 and 0.8% of healthy controls and in 9.8 and 0.7% of HIV-1-infected subjects, respectively. Of note, the delta 32/delta 32 deletion of the CCR-5 gene was detected by PCR and sequencing confirmed in a patient with progressive infection harbouring a clade B virus with SI phenotype. CONCLUSIONS delta 32/delta 32 homozygosity for the CCR-5 gene does not confer absolute protection against HIV-1 infection, suggesting that either macrophage-tropic viral strains could use coreceptors other than CCR-5 or infect independently of the presence of a functional CCR-5 coreceptor. Alternatively, primary infection sustained by T-cell-tropic isolates, although exceptional, may occur.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
March 1997, Lancet (London, England),
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
September 1997, Lancet (London, England),
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
September 1997, Lancet (London, England),
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
September 1997, Lancet (London, England),
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
June 1999, AIDS (London, England),
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
May 2000, Genetika,
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
January 2001, Clinical immunology (Orlando, Fla.),
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
February 1999, AIDS (London, England),
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
August 1996, Nature,
C Balotta, and P Bagnarelli, and M Violin, and A L Ridolfo, and D Zhou, and A Berlusconi, and S Corvasce, and M Corbellino, and M Clementi, and M Clerici, and M Moroni, and M Galli
June 1997, Lancet (London, England),
Copied contents to your clipboard!